We recently published a list of Jim Cramer’s Latest Calls: 10 Stocks to Buy or Sell. In this article, we are going to take a look at where Cardinal Health, Inc. (NYSE:CAH) stands against other stocks to buy and sell highlighted in Jim Cramer’s latest calls.
Jim Cramer in a latest program on CNBC reminded viewers about the Trump playbook in the story market and said that he never believed the President would start a new trade war with China. Cramer explained that Trump’s rhetoric has been “hot” but the reality is “cool” and his much-feared tariffs against Canada and Mexico might also not realize as the new administration said it will “study” the matter.
“The president loves the stock market; he always loves to send signals that all hell is going to break loose, and when it doesn’t, well, guess what? The market flies. This rally is built on the back of tariffs, more specifically small-than-expected tariffs that could grow bigger if countries don’t play ball. It’s built on the backs of new projects like Stargate, a new AI infrastructure initiative.”
Cramer then explained in detail why he believes Biden and his government were against top companies and how it affected the market and economy. Cramer said Trump is better for stock portfolios.
“He knows business people in Silicon Valley; he knows how things work. You may like him, you may hate him, but the bottom line is, if you’re a tech titan, Trump will take your call. In fact, he’ll call you. Biden, I don’t know if he knew who they even were, and he certainly didn’t bother to call them. In the end, I think he preferred to sue them. If you own stocks, which is why you watch me, Trump’s method is a heck of a lot better for your portfolio.”
READ ALSO: 7 Best Stocks to Buy For Long-Term and 8 Cheap Jim Cramer Stocks to Invest In
For this article, we picked 10 stocks Jim Cramer recently talked about during his programs on CNBC. With each stock, we have mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A senior physician in a modern healthcare institution administering medication to a patient.
Cardinal Health, Inc. (NYSE:CAH)
Number of Hedge Fund Investors: 40
A caller recently asked Jim Cramer about Cencora. Cramer recommended the questioner to buy Cardinal Health, Inc. (NYSE:CAH) instead.
Ariel Investment made the following comment about Cardinal Health, Inc. (NYSE:CAH) in its Q3 2022 investor letter:
“Additionally, distributor of pharmaceutical and medical products Cardinal Health, Inc. (NYSE:CAH) advanced in the period as leadership changes were viewed to be a positive for shares. Management provided a new profit outlook for Fiscal 2023 and announced an improvement plan for the medical segment. We are encouraged by these changes and think CAH’s underlying fundamentals and competitive advantages around preventative maintenance screenings and medication management will continue to improve. We believe valuations of health care companies like CAH that focus on cost optimization and promote technological efficiency across the supply chain will be rewarded over the long term.”
Overall, CAH ranks 7th on our list of stocks to buy and sell highlighted in Jim Cramer’s latest calls. While we acknowledge the potential of CAH, our conviction lies in the belief that under the radar AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CAH but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.
